RARE — Ultragenyx Pharmaceutical Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1515673 ·
Last close
$16.70
Market Cap
$1.70B
52W High
$39.89
52W Low
$12.73
ADV30
3,709,637
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 173,000,000 | 141,000,000 | -110,000,000 | -118,000,000 | 1,187,000,000 | 150,000,000 | 1,556,000,000 |
| Jun 2026 | 214,000,000 | 180,000,000 | -75,000,000 | -92,000,000 | 1,264,000,000 | 125,000,000 | 1,548,000,000 |
| Mar 2026 | 136,000,000 | 106,000,000 | -169,000,000 | -185,000,000 | 1,296,000,000 | 175,000,000 | 1,525,000,000 |
| Dec 2025 | 207,279,000 | 177,934,000 | -113,283,000 | -128,556,000 | 1,532,000,000 | 421,000,000 | 1,605,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-436,829,000
Investing CF
$-19,247,000
Financing CF
$487,841,000
CapEx
$-9,938,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.19
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,927,000,000
Inventory
$59,000,000
Receivables
$166,000,000
ST Investments
$116,000,000
EBIT TTM
$-447,217,000
Pretax Income TTM
$-529,686,000
Interest Exp TTM
$82,469,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$730,000,000
EBITDA
$-403,000,000
Free Cash Flow
$-179,376,992
Enterprise Value
$2,495,059,456
Total Cash
$266,000,000
Total Debt
$1,186,000,000
Shares Out
101,924,068
Trailing EPS
$-5.17
Book Value
$-3.70
ROE
—
ROA
-23.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 673,000,000 | -535,000,000 | -575,000,000 | 1,532,000,000 | 1,605,000,000 | -80,000,000 | -466,000,000 |
| Dec 2024 | 560,000,000 | -536,000,000 | -569,000,000 | 1,503,000,000 | 1,241,000,000 | 255,000,000 | -414,000,000 |
| Dec 2023 | 434,000,000 | -569,000,000 | -607,000,000 | 1,491,013,000 | 1,215,599,000 | 275,414,000 | -475,000,000 |
| Dec 2022 | 363,329,000 | -648,919,000 | -707,421,000 | 1,545,444,000 | 1,192,950,000 | 352,494,000 | -380,465,000 |
TTM Snapshot
Revenues TTM
$717,212,000
NetIncome TTM
$-585,969,000
OpCashFlow TTM
—
Assets (Latest)
$1,264,000,000
Forward EPS
$1.12
Max Pain — expiry 2026-12-18
max pain strike: $15.00 · spot: $17.73 · call oi: 7,213 · put oi: 2,705
Expected Move to 2026-12-18:
±$2.33
(13.11%) —
implied range
$15.41 –
$20.05
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SUPN | Supernus, Inc. | $1.69B | $29.04 | — |
| BRVE | Braveheart Bio, Inc. | $1.69B | $18.78 | — |
| SDGR | Schrodinger, Inc. | $1.68B | $25.66 | — |
| STOK | Stoke Therapeutics, Inc. | $1.73B | $26.41 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
News headlines (Yahoo Finance, 1h cache)
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
2026-11-17 08:12 · Yahoo
Ultragenyx to Participate at Investor Conferences in London
2026-11-11 13:30 · Yahoo
Mereo BioPharma Reports Third Quarter 2026 Financial Results
2026-11-09 13:00 · Yahoo
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare P
2026-11-06 08:30 · Yahoo
Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
2026-11-05 17:03 · Yahoo
Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions
2026-11-04 16:12 · Yahoo
Ultragenyx (RARE) Q3 2026 Earnings Call Transcript
2026-11-04 15:29 · Yahoo
Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)
2026-11-04 13:10 · Yahoo
Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds
2026-11-04 11:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.